Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab
- 22 March 2013
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 20 (6), 975-980
- https://doi.org/10.1111/ene.12132
Abstract
Background and purpose Vaccination against infection becomes important in patients with neuromyelitis optica spectrum disorder (NMOSD) because they are at an increased risk of infection due to long‐term immunosuppressive therapy. However, it is unclear whether NMOSD patients under immunosuppression therapy show proper antibody formation after vaccination. Thus the antibody formation after influenza A (H1N1) vaccination in patients with NMOSD receiving rituximab was evaluated. Methods The study enrolled 26 patients with NMOSD, nine with multiple sclerosis and eight healthy controls. The enrolled patients had been treated with rituximab (n = 16), mycophenolate mofetil (n = 5), azathioprine (n = 6) and interferon‐β (IFN‐β) (n = 8). Antibodies against the H1N1 influenza virus were measured in the serum drawn just before (T0) and between 3 and 5 weeks after (T1) vaccination. The immunization states for hepatitis B virus surface antigen, measles and tetanus during the treatment period were also tested. Results The rituximab group showed significantly lower geometric mean titer, seroprotection rate and mean fold increase than the azathioprine group, IFN‐β group and healthy controls, and a lower seroconversion rate than the IFN‐β group. This decrease in vaccination efficacy was also shown in patients receiving mycophenolate mofetil. The immunization state for hepatitis B virus surface antigen, measles and tetanus remained the same during the treatment period with each drug, suggesting that these treatments do not affect previously formed immunity. Conclusion This study shows a severely hampered humoral immune response to H1N1 influenza vaccine in patients with NMOSD treated with rituximab, although the vaccination itself is safe in these patients.Keywords
This publication has 25 references indexed in Scilit:
- Effect of rituximab on human in vivo antibody immune responsesJournal of Allergy and Clinical Immunology, 2011
- Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin’s Lymphoma Patients Treated with Rituximab-Containing RegimensThe Journal of Immunology, 2011
- New Insights into Neuromyelitis OpticaJournal of Clinical Neurology, 2011
- Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical TrialsThe Journal of Rheumatology, 2010
- Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugsClinical Transplantation, 2010
- Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trialArthritis & Rheumatism, 2009
- Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximabArthritis & Rheumatism, 2009
- Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximabAnnals Of The Rheumatic Diseases, 2007
- A Single Cycle of Rituximab for the Treatment of Severe PemphigusThe New England Journal of Medicine, 2007
- Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopeniasPediatric Blood & Cancer, 2007